News

SAVE THE DATE. SIAR Conference “Active participation in the processes that generate new therapies: development, evaluation and real access to dangerous treatments”. Rome 10/07/2018

SIAR (Società Italiana Attività Regolatorie) in collaboration and with the patronage of AIFA (Agenzia Italiana Del Farmaco), the Benzi Foundation and Cittadinanzattiva, has organised the conference “Active participation in the processes that generate new therapies: development, evaluation and real access to dangerous treatments”. The Conference will provide the chance to discuss the theme of the patient active participation as a new

July 3rd, 2018|

15-16th June 2018, 11th Edition of “Positive Psychology and interconnection: real and virtual communities” Days. A new opportunity to present KIDS Bari

The 11th edition of the “Positive Psychology and interconnection: real and virtual communities” Days will take place on 15th and 16th June, 2018 at the University of Bari, and it will be focused on the perspectives and the potentialities of the virtual community as facilitator rather than obstacle for the real community. Moreover, the experts

June 6th, 2018|

Misunderstanding about orphan medicines: a new document has been prepared by EMA in support of Rare Disease Day

The European Medicines Agency (EMA) has recently published a question-and-answer document to dispel any doubt on the meaning of orphan designation and other aspects related to orphan medicines Regulation in EU. The EU legislation foresees giving orphan designation for substances that could be used for treating, preventing or diagnosing a rare and serious condition. Orphan

June 4th, 2018|

The launch of the EPTRI Survey

The project ID-EPTRI (European Paediatric Translational Research Infrastructure), coordinated by Consorzio per Valutazioni Biologiche e Farmacologiche with the aim to design the framework of a new Paediatric Research Infrastructure and involving TEDDY Network as third party, foresees among its activities, the development of an ad hoc survey for outlining the current European scientific and technological

June 4th, 2018|

TEDDY is participating to EnprEMA Working Group for preparedness in paediatric clinical trials

The European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), through its Working Group for preparedness in paediatric clinical trials, is performing different actions aimed to facilitate the conduct of paediatric clinical studies focusing on identification and resolution of barriers to drug development in children. TEDDY Network is member of this Working Group

June 4th, 2018|

Participation in the Enpr-EMA pilot of the model for industry/network communication

The Working Groups 3 (Establish collaboration between Enpr-EMA networks and industry) and 5 (Sharing good practices within Enpr-EMA and with industry) of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) has launched an initiative to try to enhance communication between industry and networks. For this purpose, the experts participating to this

June 4th, 2018|

The 10th Conference of the European Paediatric Formulation Initiative (EUPFI) “Formulating better medicines for children” will be held in September 2018

The European Paediatric Formulation Initiative (EUFPI) in partnership with International for Pharmaceutical Technology will organize its 10th Conference entitled “Formulating better medicines for children” on 11-13 September 2018 at the University College London School of Pharmacy. The event will foresee the succession of workshops and Plenary Lecturers that will allow to deepen some fundamental themes

June 4th, 2018|

EUFEPS Annual Meeting 2018 in Athens, May 24-26

The European Federation for Pharmaceutical Sciences (EUFEPS) held its annual meeting on 24-26 May 2018 in Athens in collaboration with Conference Co-chair Prof. Panos Macheras supported by University of Athens and with parallel tracks organized by EUFPES Networks. The theme of the event was “Crossing Barriers for Future Medicines” and covered some interesting topics such

June 4th, 2018|

FDA Recommends Early, Pre-Approval Trials in Pediatrics for Systemic Dermatitis Drugs

A new effort to speed up paediatric drug development and arise awareness on the importance of clinical and pre-clinical paediatric trials has been done by the Food and Drugs Administration (FDA) that published a new draft guidance recommending early, pre-approval trials in pediatrics for systemic dermatitis drugs. This guidance addresses FDA’s current thinking about the

June 4th, 2018|